Regulation of Dual-Use Biotechnology Research Oversight in China

1. Introduction

Dual-use biotechnology research refers to scientific research that can produce beneficial outcomes, such as vaccines, medicines, and disease prevention, but could also be misused to cause harm. Examples include genetic engineering, pathogen modification, synthetic biology, gene synthesis, and research that increases the transmissibility or pathogenicity of microorganisms.

China regulates dual-use biotechnology through a combination of national security legislation, biosafety rules, laboratory controls, human genetic resource regulations, and research ethics requirements. The principal objective is to promote scientific innovation while preventing biological threats, accidental pathogen release, and the deliberate misuse of biotechnology.

Unlike a single-purpose licensing system, China's framework distributes oversight among several authorities, depending on the research activity and the biological risks involved.

2. Principal Legal Framework

A. Biosecurity Law of the People's Republic of China 2020

The Biosecurity Law, adopted on 17 October 2020 and effective from 15 April 2021, is the central statute governing biological risks in China.

It establishes a comprehensive framework for preventing and managing threats arising from biotechnology, infectious diseases, laboratories, and biological resources.

Its principal objectives include:

Preventing and controlling major infectious diseases and biological threats.

Strengthening biosafety management in laboratories and research institutions.

Regulating biotechnology research, development, and application.

Establishing monitoring, early-warning, and emergency-response mechanisms.

Protecting biological resources and preventing biological risks to national security.

The law requires relevant institutions to implement biosafety management systems, assess risks, train personnel, maintain appropriate facilities, and report qualifying biosafety incidents.

Relevance to dual-use research: Research that is legitimate from a scientific perspective may still require additional risk assessment when its methods or results could facilitate the development of biological weapons or dangerous pathogens.

B. Regulations on Biosafety Management of Pathogenic Microorganism Laboratories

China's Regulations on Biosafety Management of Pathogenic Microorganism Laboratories, promulgated in 2004 and subsequently amended, establish controls for laboratories handling pathogenic microorganisms.

The regulatory framework includes laboratory classification, personnel responsibilities, access restrictions, technical safeguards, and procedures for handling biological accidents.

Higher-risk laboratories are subject to more stringent requirements. Institutions must ensure that their containment arrangements are appropriate for the pathogens and procedures involved.

These controls are important where dual-use research involves pathogens that could cause severe disease, spread between humans, or create substantial public-health risks.

3. Institutional Oversight and Risk Assessment

Oversight involves several government bodies, depending on the research activity.

National Health Commission (NHC): Oversees public-health matters, infectious disease prevention, and relevant medical research.

Ministry of Science and Technology (MOST): Responsible for science and technology policy and relevant research governance functions.

Ministry of Agriculture and Rural Affairs: Regulates relevant agricultural biotechnology activities.

Ministry of Ecology and Environment: Oversees environmental risks associated with relevant genetically modified organisms.

Public security and other competent authorities: May become involved where biological threats, illegal activities, or national security concerns arise.

Under the Biosecurity Law, biotechnology research and development must comply with applicable biosafety requirements. Institutions should assess risks, establish internal responsibility systems, and ensure that research activities receive the required review and authorization.

4. Dual-Use Research and Ethical Responsibilities

Dual-use oversight requires researchers to consider both the scientific benefits and the potential harmful consequences of their work. Particular concern arises when research could increase a pathogen's ability to cause disease, expand its host range, or undermine existing public-health protections.

Research institutions should therefore establish procedures for:

Assessing biological risks before research begins.

Reviewing research proposals through appropriate biosafety and ethics committees.

Restricting access to sensitive materials and information.

Monitoring experiments and maintaining accurate records.

Reporting accidents, unauthorized activities, and other incidents where required.

Reviewing whether publication or transfer of research materials creates additional risks.

China's Biosecurity Law also provides a national framework for monitoring biological risks and responding to emergencies. Not every dual-use project is automatically prohibited; its legality depends on the nature of the work and the applicable controls.

5. Relevant Cases and Legal Precedents

Case 1: He Jiankui Gene-Editing Case (2019)

In December 2019, the Shenzhen Nanshan District People's Court convicted He Jiankui and two collaborators of illegal medical practice involving human embryo gene editing. He received three years' imprisonment and a fine.

Legal principle: Biotechnology research must comply with applicable legal, medical, and ethical requirements. Scientific innovation does not exempt researchers from legal accountability.

Relevance: Although this was not a direct dual-use research prosecution, it demonstrates the importance of institutional supervision, ethical review, and accountability in high-risk biotechnology.

Case 2: SARS-Related Biosafety Failures in China (2004)

In 2004, laboratory-associated SARS infections in Beijing raised serious concerns about laboratory biosafety and institutional oversight. Chinese authorities investigated the incidents, and officials faced disciplinary consequences.

Legal significance: The episode highlighted the dangers of inadequate laboratory controls, training, and incident management. It is an important historical example of biosafety oversight, although it should not be presented as a judicial precedent specifically concerning dual-use research.

Relevance: Dual-use governance must address not only deliberate misuse but also accidental exposure, unsafe laboratory practices, and failures to report incidents.

6. Conclusion

China's dual-use biotechnology oversight rests principally on the Biosecurity Law 2020, pathogenic microorganism laboratory regulations, applicable research ethics requirements, and relevant export-control rules. Its approach combines risk assessment, institutional responsibility, laboratory safety, and government supervision.

Important distinction: There is limited publicly documented Chinese case law directly addressing dual-use biotechnology research as a separate legal category. The cases discussed above are related precedents and historical enforcement examples, not direct judicial rulings on dual-use research itself.